In Vivo CRISPR Screening Identifies the Glutamate Receptor GRIA2 as Promoting Peritoneal Metastasis of Gastric Cancer via Calcium-Dependent β-Catenin Activation - PubMed
2 days ago
- #Gastric Cancer
- #Metastasis
- #CRISPR
- In vivo CRISPR screening identified GRIA2 as a key driver of gastric cancer peritoneal metastasis.
- GRIA2 promotes cancer cell migration, invasion, stemness, and adhesion via glutamate-dependent activation.
- Glutamate from cancer-associated fibroblasts activates GRIA2, leading to calcium influx and β-catenin stabilization.
- Pharmacological inhibition of AMPA receptors (e.g., NBQX, Selurampanel) suppressed metastasis in mouse models.
- High GRIA2 expression in patients correlates with poor prognosis and β-catenin/GSK-3β pathway activation.